The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) therapy market over the 10-year forecast period. Key therapies expected to fuel growth are the approved CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), Tecartus (Gilead), and Breyanzi (Bristol Myers Squibb), as well as targeted agents Polivy (Roche), Monjuvi / Minjuvi (MorphoSys / Incyte), Xpovio (Karyopharm Therapeutics), and Zynlonta (ADC Therapeutics). In addition, combinations incorporating the BTK inhibitors Imbruvica (Janssen / AbbVie) and Calquence (AstraZeneca), and the BCL-2 inhibitor Venclexta / Venclyxto (AbbVie / Roche) will enter the market, resulting in a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of novel emerging therapies (such as the bispecific antibodies glofitamab [Roche], mosunetuzumab [Roche], epcoritamab [Genmab / AbbVie], and non-covalent BTK inhibitor pirtobrutinib [Loxo Oncology / Eli Lilly]) will further fragment the R/R DLBCL, FL and CLL / SLL patient settings and create intense competition.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.
Epidemiology: Diagnosed incidence of follicular lymphoma (FL) (including transformed FL), chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL).
Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.
Emerging therapies: Phase I/II: 19 drugs; Phase III / PR: 11 drugs.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.